Research Article
New Enhancement beyond Radiation Field Improves Survival Prediction in Patients with Post-Treatment High-Grade Glioma
Table 1
Baseline characteristics of HGG patients (n = 142).
| | Characteristics | Mean/median (standard deviation/95% CI), n (%) |
| | Age (years) | 47.47 (14.35) | | Radiation dose (Gy) | 58.92 (5.91) | | PFS (months) | 345 (382–538) | | OS (months) | 540 (561–720) |
| | Gender | | Female | 63 (44.37%) | | Male | 79 (55.63%) |
| | IDH (N = 64) | | Wild | 45 (69.35%) | | Mutation | 19 (30.65%) |
| | Histopathology | | Anaplastic oligodendroglioma | 43 (30.28%) | | Anaplastic astrocytoma | 30 (21.13%) | | Anaplastic pleomorphic xanthoastrocytoma | 5 (3.52%) | | Glioblastoma | 64 (45.07%) |
| | Nonenhanced T2/FLAIR hyperintensity lesions | | Stable or decrease | 80 (54.93%) | | Increase | 62 (45.07%) |
| | Enhancement of residual cavity wall | | Nonenhancement or thin-linear enhancement | 64 (45.07%) | | Thick-linear or nodular enhancement | 78 (54.93%) |
| | PWI (N = 58) | | Progress | 47 (81.03%) | | Stable | 11 (18.97%) |
| | NERF | | Negative | 70 (49.30%) | | Positive | 72 (50.70%) |
| | nSVZE | | Negative | 65 (45.77%) | | Positive | 77 (54.26%) |
| | Outcome | | Remain alive till due time | 90 (63.38%) | | Dead | 52 (36.62%) |
|
|
HGG, high-grade glioma; CI, confidence interval; PFS, progression-free survival; OS, overall survival; IDH, isocitrate dehydrogenase; FLAIR, fluid-attenuated inversion recovery; NERF, new enhancement beyond the radiation field; nSVZE, new subventricular zone enhancement.
|
